Daniel Ward
Latest Articles
Biotech Weekly: The Nasdaq Sub-$10 Million Market Cap Club
Biotech Weekly: Top Value Biotech Picks For 2016
Biotech Weekly: Recapping Small- And Mid-Cap Presentations At SABCS
Biotech Weekly: Think Like A Trader
Biotech Weekly: Stories To Track Into SABCS, Oncothyreon And Puma Biotechnology
Biotech Weekly: Stories To Track Into SABCS, Celsion Corporation
Sophiris Bio: While Failure To Meet P3 Primary Endpoint Is Likeliest Result, More Upside Scenarios Exist
Anavex Life Sciences: Unbridled Exuberance Requires A Reality Check For Investors In This Biotech
OXiGENE: A Frustrating Company That Remains Cheap
Biotech Weekly: Top Value Biotech Picks Starting Q4 2015
Biota Sowing Seeds For Success As Market Continues To Ignore Progress
Capnia: Poor Capital Structure And Future Funding Issues Cloud Company's Future
Biotech Weekly: Reviewing The <1x Book Biotech Screen
Roka Bioscience: My Best Long-Term Small Cap Biotech Turnaround Play
AEterna Zentaris: CEO Says Stay Away, You Should Listen
Biotech Weekly: Position Management And What To Do When You're In The Red
Defending Cumberland Pharmaceuticals And Upgrading To A Buy In Front Of Q2 Earnings
Venaxis Remains Inexpensive After The FDA Setback
Biotech Weekly: 7 Stock-Specific Reasons Why You Shouldn't Buy That Speculative Biotech
Hemispherx Biopharma: How One Filing Can Show You To Stay Far Away
Investors Remain Overly Skeptical, Leaving DARA Biosciences Undervalued After The Merger Announcement
Biotech Weekly: Top Value Biotech Picks Starting Q3 2015
Biotech Weekly: Taking A Pulse On Biotech And Speculating On Speculation
Cumberland Pharmaceuticals: Love The Company, But Upside Is Limited
Biotech Weekly: Top Picks YTD From The Biotech Charity Contest
Why I Purchased Stock In Celsus Therapeutics
Biotech Weekly: Tracking Institutional Money Flow Into ASCO
OncoGenex Is A Buy As Thesis Remains Intact
Deteriorating Capital Structure And Lack Of Catalysts Make AEterna Zentaris A Sell
Sticking With Cumberland Pharmaceuticals After The Q1 Update
Biota Pharmaceuticals: A Cash-Rich Biotech With An Expanding Pipeline
Checking In On OXiGENE After The Q1 Update